Brain
Tulane Cancer Center Clinical Research Protocols Tulane Cancer Center's Office of Clinical Research (504) 988-6121 |
|
Brain |
Lung |
See also: Tulane's ACCTION regional clinical trials network.
| LN01.1 | (Metastases) Local therapy for limited metastatic disease to the brain: a phase II study of surgery, SRS and SRT in favorable patients. Tulane investigator-initiated study. |
| NSABP B-36 | A clinical trial of adjuvant therapy comparing six cycles of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients with node-negative breast cancer. |
| SWOG S0221 | Phase III trial of continuous schedule ACC + G vs. q 2 week schedule AC, followed by paclitaxel given either every 2 weeks or weekly for 12 weeks as postoperative adjuvant therapy in node-positive or high risk node negative breast cancer |
ECOG PACCT-1 |
Program for the assessment of clinical cancer tests (PACCT-1): trial assigning individualized options for treatment: The TAILORx Trial |
| GOG 0136 | Acquisition of human gynecologic specimens and serum to be used in studying the causes, diagnosis, prevention and treatment of cancer, all stages |
GOG 0219 |
A phase III randomized trial of weekly cisplatin and radiation versus cisplatin and tirapazamine and radiation in stage IB2, IIA, IIB, IIIB and IVA cervical carcinoma limited to the pelvis |
| GOG 0209 | Randomized phase III trial of doxorubicin/cisplatin/paclitaxel and G-CSF versus carboplatin/paclitaxel in patients with stage III and IV or recurrent endometrial cancer |
| GOG 0136 | Acquisition of human gynecologic specimens and serum to be used in studying the causes, diagnosis, prevention and treatment of cancer, all stages |
| NSABP R-04 | A clinical trial comparing pre-operative radiation therapy and capecitabine with preoperative radiation therapy and continuous intravenous infusion (CVI) of 5-fluorouracil (5-FU) in the treatment of patients with operable carcinoma of the rectum |
Hematopoietic Failure and Genetic Disease Transplant Studies
BMT 2001-01 |
G-CSF Primed Donor Leukocyte Infusion (G-DLI) for Treatment of Relapsed Hematologic Malignancy After Allogeneic Stem Cell Transplant. Tulane investigator-initiated study. |
BMT 2001-03 |
Phase II trial of CD34 selected peripheral blood progenitor cells with immunoablation in the treatment of severe autoimmune disease . Tulane investigator-initiated study. |
| BMT 98-1 Transplant |
Bone marrow transplantation for high-risk
LEUKEMIAS with busulfan, CTX, and Etoposide Tulane investigator-initiated study |
| SWOG S9910 | Leukemia centralized reference laboratories and tissue repositories consent to perform cellular and molecular studies in leukemia patients |
SWOG S0106 |
A phase III study of the addition of gemtuzumab ozogamicin (Mylotarg) induction therapy versus standard induction with daunomycin and cytosine arabinoside followed by consolidation and subsequent randomization to post-consolidation therapy with gemtuzumab ozogamicin (Mylotarg) or no additional therapy for patients under age 56 with previously untreated de novo acute myeloid leukemia (AML) |
|
BMT
2000-01 Transplant |
(CML in the first chronic phase.) Allogeneic BMT
for chronic myelogenous leukemia using primed bone marrow stem cells. Tulane investigator-initiated study. |
| CYC 202-06-04 | A phase IIb randomized study of oral seliciclib in patients with previously treated non-small cell lung cancer |
Non-small cell
| SWOG E5597 | (Post-op, Stage IA, pT1N0 or Stage IB, pT1N0) Phase III chemoprevention trial of selenium supplementation in persons with resected stage I non-small-cell lung cancer" |
DOCOX L00716 |
A phase II multicenter study of docetaxel and oxaliplatin in combination with bevacizumab as first-line treatment in chemotherapy-naive subjects with unresectable locally advanced and/or recurrent (stage IIIB) or metastatic (stage IV) non squamous-cell histology non-small cell lung cancer (NSCLC) (Sanofi-Aventis) |
BMT 99-1 |
Immuno-transplantation for lymphoid malignancy using allogeneic blood stem cells |
| SWOG 9245 | Central lymphoma repository tissue procurement protocol for relapse or recurrent disease, ancillary |
| SWOG 9007 | Cytogenetic studies in leukemia patients - ancillary |
| CMC 544 | A phase I/II study of CMC-544 administered in combination with rituximab in subjects with follicular or diffuse large B-cell non-Hodgkin's lymphoma (Wyeth Pharmaceuticals) |
| PDX-008 | A Multi-Center Phase 2 Open-Label Study of (RS)-10-Propargyl-10-Deazaaminopterin (pralatrexate) with Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma (ALLOS) |
Non-Hodgkin's
BMT 99-2 |
Autologous transplantation for non-Hodgkin's
lymphoma. The role of in vivo purging with monoclonal antibody. |
Hodgkin's
SWOG 0410 |
Tandem Autologous Stem Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin's Disease (A BMT Study), Phase 2 |
SWOG S0309 |
Myeloma specimen repository protocol, ancillary |
BMT 99-1 |
Immuno-transplantation for
lymphoid malignancy using allogeneic blood stem cells. |
| HSO1.02 Transplant |
Autologous peripheral stem
cell transplantation for multiple myeloma: safety and efficacy of the
use of rituxan for in vivo purging prior to high-dose
chemotherapy and peripheral stem cell transplantation in the treatment
of multiple myeloma. |
| SWOG S0115 | A phase II trial evaluating modified high dose melphalan (100 mg/m2) and autologous peripheral blood stem-cell supported transplantation (SCT) for high risk patients with multiple myeloma and/or light chain amyloidosis (AL amyloidosis) (A BMT study) (M0591) |
| GOG 0136 | Acquisition of human gynecologic specimens and serum to be used in studying the causes, diagnosis, prevention and treatment of cancer, all stages |
| GOG 0175 | A randomized phase III trial of IV carboplatin (AUC 6) and paclitaxel 175 mg/m2 q 21 days x 3 courses plus low dose paclitaxel 40 mg/m2/wk versus IV carboplatin (AUC 6) and paclitaxel 175 mg/m2 q 21 days x 3 courses plus observation in patients with early stage ovarian carcinoma |
| GOG 0218 | A phase III trial of carboplatin and paclitaxel plus placebo versus carboplatin and paclitaxel plus concurrent bevacizumab (NSC #704865, IND #7921) followed by placebo, versus carboplatin and paclitaxel plus concurrent and extended bavacizumab in women with newly diagnosed, previously untreated, stage III (sub optimal) and all stage IV epithelial ovarian or primary peritoneal cancer, sub optimal advanced stage |
| GOG 0212 | A randomized phase III trial of maintenance chemotherapy comparing 12 monthly cycles of single agent paclitaxel or xyotax (CT-2103) (IND# 61013), versus no treatment until documented relapse in women with advanced ovarian or primary peritoneal cancer who achieve a complete clinical response to primary platinum/taxane chemotherapy |
| GOG 0136 | Acquisition of human gynecologic specimens and serum to be used in studying the causes, diagnosis, prevention and treatment of cancer, all stages |
GOG 0174 |
A randomized phase III trial of weekly parenteral methotrexate versus "pulsed" dactinomycin as primary management for low risk gestational trophoblastic neoplasia |
NOTICE TO ACCTION NETWORK RESEARCHERS:
NIH policy requires all individuals
involved in research with humans that is funded by the NIH to receive
education in the protection of human research participants. To comply
with this requirement, the NSABP is requiring that all NSABP investigators (any physician responsible for administering therapy and/or for consenting patients on
NSABP treatment protocols) must complete training in the protection of
human research participants. Acceptable forms of training include the
NIH Web site training program at http://ohsr.od.nih.gov/cbt.
This is also available in the Member's Area of the NSABP Web site at http://www.nsabp.pitt.edu and on
the Tulane Web site at http://www.som.tulane.edu/irb/program.
Return to the top of this page.
Return to the Tulane
Cancer Center homepage.
Calendars
Clinical Trials Faculty
Links
Location
News
Search
Site index
This page is http://www.som.tulane.edu/cancer/protocols/default.html
This page was last updated on October 20, 2006.